Klinisk Biokemi i Norden · 1 2018
| 13
adapted to the different digital channels and people
are struggling to cope with it. With examples from
the world of sales and marketing, lessons about how
to manage this transitions are given.
The Lorentz Eldjarn Prize Competition for Best
Publication 2018:
In this session, three most promi-
nent studies published in the journal
The Scandina-
vian Journal of Clinical and Laboratory Investigation
(
SJCLI
) will be presented. The twenty most cited
articles in
SJCLI
during 2013-2017 are pre-selected for
further evaluation by a prize committee, which then
nominates three articles to be presented at NFKK2018
in Helsinki. The first author of each of the articles are
invited to present their study, especially focusing on
the scientific impact of the study on the development
within the actual field of research. The nominees shall
also focus on how the actual article has influenced
their own later works.
Lorentz Eldjarn was the second managing editor of
SJCLI for 16 years during 1967-1980. He passed away
2008 and together with his wife Torunn Eldjarn left
to the NFKK funds to be used for promoting publi-
cation of Nordic studies in the SJCLI. The Lorentz
Eldjarn Prize Competition for Best Publication is also
intended to support and promote the international
distribution of SJCLI. The Prize is awarded biannu-
ally to the first author of the best article published in
SJCLI. At least one of the authors has to be engaged
in activities related to medical biochemistry at an
institution in one of the Nordic countries. Based on
the scientific quality of the study and the clarity of
the presentations the prize committee selects the win-
ner, the second and the third prizes. The recipients
of the Prize shall be announced at the banquet of the
NFKK2018. The prize sum is payed from the Lorentz
Eldjarn Fund.
Diabetes and the laboratory:
Professor Mikael
Knip (University of Helsinki) will chair this session
focusing on the role of laboratory in diagnosis and
follow-up of diabetes. Professor Knip’s research group
has contributed to the present understanding of the
diabetic disease process and reported important
findings in the area of type 1 diabetes prediction
and prevention. Type 1 diabetes is the most common
serious disease among children and adolescents in
the European countries. Globally, the incidence is
highest in the Northern Europe, but the incidence
rate is continuously increasing all over our conti-
nent. The number of new cases with type 1 diabetes
among European children younger than five years of
age has been predicted to double between 2005 and
2020. The etiology is largely unknown; no efficient
primary prevention is available and nobody has so
far been cured. In spite of heavy treatment with
multiple daily insulin injections, adapted to regular
meals with suitable content and monitored by several
daily blood glucose tests, it is in practice impossible
to avoid both life-threatening acute complications
with sudden unconsciousness, and late diabetes
complications affecting kidney, nerves and heart and
leading to disabilities and increased mortality. The
disease process starts months and years before any
symptoms of diabetes appear. Deeper insights are
needed into the process resulting in clinical disease
to be able to develop effective preventive measures.
New technologies provide promising prospects for
generating novel knowledge that can be translated
into successful prevention and treatment.
International collaboration:
In the International
collaboration session we will hear presentations
from international organizations gathering together
experts in laboratory medicine. We will hear an
overview and update of current activities from IFCC
(International Federation of Clinical Chemistry and
Laboratory Medicine), EFLM (European Federation
of Clinical Chemistry and Laboratory Medicine) and
NFKK (Nordisk Forening for Klinisk Kemi). The ses-
sion is a great place to learn how these organizations
work, what they can offer for you in your daily work
and even how to participate in the activities of the
working groups. In the end of the session we are plan-
ning to reserve time for free discussion about current
issues in laboratory medicine. This session, thereafter,
is an excellent opportunity to meet international col-
leagues and establish new connections.
Company sessions:
The NFKK2018 Organizers have
been enthusiastic to have a possibility to invite diag-
nostic companies, not only to exhibit their products
and services, but also to complement the scientific
contents of the congress program. Several companies
will organize workshops as separate sessions under
interesting topics with scientific background and
practical approach.
